天美传媒

Abstract

Interstitial Lung Disease (ILD) encompasses a diverse group of pulmonary disorders characterized by inflammation and fibrosis of the lung interstitium. Early detection and accurate monitoring of ILD are critical for optimizing treatment outcomes and improving patient prognosis. Recent advances in biomarker research have identified several novel biomarkers that show promise in enhancing the early detection, diagnosis, and management of ILD. Recent advancements in biomarker research offer promising new tools for the early detection and monitoring of Interstitial Lung Disease (ILD). Novel biomarkers, including serum protein levels, microRNAs, and specific autoantibodies, have shown potential in improving diagnostic accuracy and tracking disease progression. Biomarkers such as Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) are emerging as valuable indicators for identifying early disease stages and evaluating treatment responses. This abstract highlights the impact of these innovative biomarkers on enhancing ILD management and underscores the need for further validation and integration into clinical practice.